Measurement of constitutive activity of BMP type I receptors

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 281-293

  De Gorter, David J J ^a   Van Dinther, Maarten ^a   Ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ACTIVIN RECEPTOR LIKE KINASE 2; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; PENICILLIN G; PROTEIN SERINE THREONINE KINASE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADENOVIRUS; BOOK; CELL DIFFERENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; GENE CONSTRUCT; GENE MUTATION; HUMAN; NONHUMAN; OSSIFYING MYOSITIS; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SPECTROPHOTOMETRY; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 78049264338     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00015-0     Document Type: Chapter

References (21)

1. Chen Y.G., Liu F., Massague J. Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J. 1997, 16:3866-3876.
2. Fujii M., Takeda K., Imamura T., Aoki H., Sampath T.K., Enomoto S., Kawabata M., Kato M., Ichijo H., Miyazono K. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol. Biol. Cell 1999, 10:3801-3813.
3. Gazzerro E., Canalis E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 2006, 7:51-65.
4. Huse M., Chen Y.G., Massague J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 1999, 96:425-436.
5. Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L., Delai P., Fastnacht-Urban E., Forman S.J., Gillessen-Kaesbach G., Hoover-Fong J., Koster B., et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 2009, 30:379-390.
6. Korchynskyi O., Ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem. 2002, 277:4883-4891.
7. Okadome T., Oeda E., Saitoh M., Ichijo H., Moses H.L., Miyazono K., Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-β type I receptor in vivo. J. Biol. Chem. 1996, 271:21687-21690.
8. Persson U., Izumi H., Souchelnytskyi S., Itoh S., Grimsby S., Engstrom U., Heldin C.H., Funa K., Ten Dijke P. The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 1998, 434:83-87.
9. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., Dimeco F., Vescovi A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
10. Sambrook J., Russel D.W. Commonly Used Techniques in Molecular Cloning. Molecular Cloning: A Laboratory Manual. 2001, A8.40-A8.55. Cold Spring Harbor Press, Cold Spring Harbor, New York.
11. Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Cho T.J., Choi I.H., Connor J.M., Delai P., Glaser D.L., LeMerrer M., Morhart R., Rogers J.G., et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 2006, 38:525-527.
12. Sieber C., Kopf J., Hiepen C., Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009, 20:343-355.
13. Urist M.R. Bone: Formation by autoinduction. Science 1965, 150:893-899.
14. van Dinther M., Visser N., de Gorter D.J., Doorn J., Goumans M.J., de Boer J., Ten Dijke P. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the bmp type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 2010, 25:1208-1215.
15. Wang T., Li B.Y., Danielson P.D., Shah P.C., Rockwell S., Lechleider R.J., Martin J., Manganaro T., Donahoe P.K. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 1996, 86:435-444.
16. Wieser R., Wrana J.L., Massague J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995, 14:2199-2208.
17. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: Molecular clones and activities. Science 1988, 242:1528-1534.
18. Wrana J.L., Tran H., Attisano L., Arora K., Childs S.R., Massague J., O'Connor M.B. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol. Cell. Biol. 1994, 14:944-950.
19. Xu R.H., Sampsell-Barron T.L., Gu F., Root S., Peck R.M., Pan G., Yu J., Antosiewicz-Bourget J., Tian S., Stewart R., Thomson J.A. NANOG is a direct target of TGFβ/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008, 3:196-206.
20. Yu P.B., Deng D.Y., Lai C.S., Hong C.C., Cuny G.D., Bouxsein M.L., Hong D.W., McManus P.M., Katagiri T., Sachidanandan C., Kamiya N., Fukuda T., et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 2008, 14:1363-1369.
21. Yu P.B., Hong C.C., Sachidanandan C., Babitt J.L., Deng D.Y., Hoyng S.A., Lin H.Y., Bloch K.D., Peterson R.T. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4:33-41.